AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer

被引：0
|
作者：
Smyth, Lillian M.
Oliveira, Mafalda
Ciruelos, Eva
Tamura, Kenji
El-Khoueiry, Anthony
Mita, Alain
You, Benoit
Renouf, Daniel J.
Sablin, Marie-Paule
Lluch, Ana
Mayer, Ingrid A.
Bando, Hideaki
Yamashita, Hiroko
Ambrose, Helen
de Bruin, Elza
Carr, T. Hedley
Corcoran, Claire
Foxley, Andrew
Lindemann, Justin P. O.
Maudsley, Rhiannon
Pass, Martin
Rutkowski, Andrzej
Schiavon, Gaia
Banerji, Udai
Scaltriti, Maurizio
Taylor, Barry S.
Chandarlapaty, Sarat
Baselga, Jose
Hyman, David M.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Natl Canc Ctr, Tokyo, Japan
[5] Univ Southern Calif, Los Angeles, CA USA
[6] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[7] Univ Lyon 1, Inst Cancerol, Hosp Civils Lyon, CITOHL, Lyon, France
[8] British Columbia Canc Agcy, Vancouver, BC, Canada
[9] Inst Curie, Paris, France
[10] Inst Curie, St Cloud, France
[11] Hosp Clin Univ, Valencia, Spain
[12] INCLIVA Hlth Res Inst, Valencia, Spain
[13] Univ Valencia, Valencia, Spain
[14] CIBERONC ISCIII, Valencia, Spain
[15] Vanderbilt Breast Ctr, Nashville, TN USA
[16] Hosp East, Natl Canc Ctr, Chiba, Japan
[17] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[18] AstraZeneca, Cambridge, England
[19] Inst Canc Res, London, England
[20] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-21-32
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Targeting new therapies in combination with hormonal therapies for ER-positive breast cancer
    Dowsett, M
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S13 - S13
  • [42] Combination Treatment with Fulvestrant and Various Cytotoxic Agents Has a Synergistic Effect in ER-Positive Breast Cancer Cell Lines In Vitro and In Vivo
    Ikeda, H.
    Taira, N.
    Nogami, T.
    Shien, T.
    Doihara, H.
    Miyoshi, S.
    CANCER RESEARCH, 2010, 70
  • [43] Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
    Liu, Ying
    Zhang, Ning
    Zhang, Hanwen
    Wang, Lijuan
    Duan, Yi
    Wang, Xiaolong
    Chen, Tong
    Liang, Yiran
    Li, Yaming
    Song, Xiaojin
    Li, Chen
    Han, Dianwen
    Chen, Bing
    Zhao, Wenjing
    Yang, Qifeng
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 3535 - 3545
  • [44] ProCAID: A phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone (DP) chemotherapy for metastatic castration resistant prostate cancer (mCRPC).
    Crabb, Simon J.
    Birtle, Alison J.
    Martin, Karen
    Downs, Nichola
    Bowers, Megan
    Ratcliffe, Ian
    Ellis, Mary
    Griffiths, Gareth
    Thompson, Stuart
    Khoo, Vincent
    Jones, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [45] A phase I study evaluating continuous and intermittent AZD2014 in combination with fulvestrant in patients with ER plus advanced metastatic breast cancer
    Patel, Manish
    Hamilton, Erika
    LoRusso, Patricia M.
    Gluck, W. Larry
    Jones, Suzanne F.
    Kittaneh, Muaiad
    Cosulich, Sabina
    Harrington, Elizabeth A.
    Green, Stephen
    Burke, Wendy
    Strickland, Donald K.
    Oelmann, Elisabeth
    Burris, Howard A.
    CANCER RESEARCH, 2015, 75
  • [46] A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type
    Zhang, Yuncheng
    Zheng, Yuanwen
    Faheem, Ali
    Sun, Tiantong
    Li, Chunyou
    Li, Zhe
    Zhao, Diantang
    Wu, Chao
    Liu, Jun
    ONCOLOGY LETTERS, 2016, 11 (03) : 1685 - 1692
  • [47] Androgen and ESR1 mutant receptors mechanistically collaborate for overexpression of genes associated with poor outcomes in ER-positive metastatic breast cancer
    Fuqua, Suzanne
    Gonzalez, Thomas L.
    Gu, Guowei
    Herzog, Sarah
    Rechoum, Yassine
    Beyer, Amanda
    Edwards, David
    Lin, Hangqing
    Paul, Basil
    Kittler, Ralf
    Weigel, Nancy
    Grimm, Sandra
    Coarfa, Cristian
    Bawa-Khalfe, Tasneem
    CANCER RESEARCH, 2021, 81 (04)
  • [48] Prognostic Impact of DLC1 in ER-Positive Breast Cancer
    Gokmen-Polar, Yesim
    Gu, Xiaoping
    Nallamothu, Gouthami
    Badve, Sunil
    MODERN PATHOLOGY, 2015, 28 : 47A - 47A
  • [49] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
    Reinert, Tomas
    de Paula, Bruno
    Shafaee, Maryam Nemati
    Souza, Pedro Henrique
    Ellis, Matthew J.
    Bines, Jose
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [50] Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer
    Laine, Muriel
    Fanning, Sean W.
    Chang, Ya-Fang
    Green, Bradley
    Greene, Marianne E.
    Komm, Barry
    Kurleto, Justyna D.
    Phung, Linda
    Greene, Geoffrey L.
    BREAST CANCER RESEARCH, 2021, 23 (01)
12345